Creating 100% Pathogen Free Environments

Canmedical Secures AsepticSure Distribution Rights For Canadian Veterinary Market

Thumbnail Image Of AsepticSure MachineAsepticSure, a WHO award-winning vapor-mist decontamination and infection control technology is to be distributed in Canada by leading medical and veterinary products supplier, Canmedical.

San Francisco, CA January 25, 2012.  Medizone International, Inc. (MZEI:OB) MZEI:QB) and Canmedical, a privately owned Canadian medical and veterinarian supply company, jointly announce the signing of a detailed Letter of Understanding in which a new division of Canmedical will become an AsepticSure distributor.

Canmedical and Reliance Associates LLC have formed a joint venture to establish, fund and operate throughout Canada.  Registration of the new division, tentatively named Contamination Control Company, will be incorporated in Ontario.

Under the agreement, this new division of Canmedical will have exclusive rights to the National Canadian Veterinary Market for AsepticSure.  Additionally, Canmedical currently has a client base of fifty hospitals in Ontario and will also retain the rights to that market.

Canmedical will begin to represent AsepticSure immediately, beginning with the Ontario Veterinary Medical Association Conference, January 26, 27 and 28 in Toronto.

The OVMA convention is being held at the Westin Harbour Castle, Toronto. Medizone CEO, Edwin Marshall, and Medizone President and Director of Medical Affairs, Dr Michael E. Shannon, will be present at the convention to help support this new venture by Canmedical.

Mr. Marshall commented, “This agreement signifies a joint effort to reduce the spread of infectious animal diseases within exotic veterinary practices, zoos, animal laboratories, animal feed and transportation settings, as well as the large animal and equine. The business plan, enthusiasm and intelligence that we’ve seen from Canmedical in their approach has been impressive.

“I have no doubt that this new division of Canmedical will play a major role in decontamination and infectious disease control where animals are concerned. It’s a venture destined for significant success.”

As part of the agreement with Medizone, Canmedical has committed to an initial order of four AsepticSure systems for delivery in Q2.

Canmedical CEO Bob Simpson stated, “AsepticSure provides a perfect fit for Canmedical and will undoubtedly be embraced by the veterinary world in Canada. As a contamination control technology AsepticSure has no equal, hence the reason we chose to establish a dedicated division of our business just to accommodate what we firmly believe will be ‘explosive growth’ in the demand for AsepticSure, both in the vet industry and hospital and health care sector. We’re proud and excited to form this venture with Medizone International and can see unlimited potential going forward.”

For information on Canmedical, please contact:

Bob Simpson 001-613-358-5658     E: bob@canmedical.ca

Canmedical has been serving the Canadian hospital and vet industry, nationwide, for more than 25 yrs. Specializing in the supply, service and support of state-of-the-art digital ultrasound, autoclave and radiography equipment, Canmedical has become a national authority in the veterinary and hospital supplies field.

For press information on Medizone International, please contact:

Bruce Smeaton, Investor Relations, Medizone International, Inc.

T: 001-415-331-0202     E: bruce@medizoneint.com

Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

For more information, visit: www.medizoneint.com

Email: operations@medizoneint.com

Contact:

Medizone International, Inc. (MZEI.OB)

4000 Bridgeway, Suite 401,
Sausalito, CA 94965

Telephone: 415-331-0303

Email
: operations@medizoneint.com

Investor Relations:

John Pentony

Investor Relations,
Medizone International, Inc.

Telephone: (415) 331-0202

E: j.pentony@medizoneint.com

Media Contact:

Gary Hanauer

Media Relations,
Medizone International, Inc.

Telephone: (510) 686-1238

E: GarHan@aol.com